What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “• 100 mg orally once daily for 2 weeks on treatment followed by 2 weeks off treatment (2W/2W) in each 4-week cycle”In the company’s words, NCT07824986 on ClinicalTrials.gov
- Tested for
- Pleural Mesothelioma (2 trials), Mesothelioma (2 trials), Solid Tumor, Adult, NSCLC, Non-Pleural Mesothelioma, Non Small Cell Lung Cancer, Epithelioid Hemangioendothelioma (EHE), Adenoma and 4 more
- Main trialPhase 3
- “This randomized, open-label, multicenter Phase 3 trial will compare VT3989 with Investigator's choice of gemcitabine or vinorelbine in adults with advanced epithelioid pleural mesothelioma whose disease progressed after prior platinum-based systemic chemotherapy and immunotherapy.”In the company’s words, NCT07824986 on ClinicalTrials.gov
Other drugs for Pleural Mesothelioma
- VolrustomigAstraZeneca · Phase 3
- EB-MF-CAR-NK-01Beijing Biotech · Phase 1/2
- ISM6331InSilico Medicine Hong Kong Limited · Phase 1/2
- Alintegimod7 Hills Pharma, LLC · Phase 1/2
- TYK-01054TYK Medicines · Phase 1/2
- A2B543A2 Biotherapeutics Inc. · Phase 1/2
Coming up2
- 1 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 2 Nov 2029Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 1 May 2028 | A Phase 3 Trial in Advanced Epithelioid Mesothelioma | |
| Phase 1/2Recruiting | 2 Nov 2029 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026